June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Latanoprostene Bunod 0.024% Significantly Reduces and Maintains Mean Diurnal Intra-Ocular Pressure (IOP) Compared to Latanoprost 0.005% in Subjects with Open Angle Glaucoma or Ocular Hypertension
Author Affiliations & Notes
  • L Jay Katz
    Glaucoma, Wills Eye Institute and Department of Ophthalmology, Thomas Jefferson University, Philadelphia, PA
  • Paul Kaufman
    Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI
  • Tuyen Ong
    Bausch & Lomb, Madison, NJ
  • Baldo Scassellati-Sforzolini
    Bausch & Lomb, Madison, NJ
  • Jason Vittitow
    Bausch & Lomb, Madison, NJ
  • Footnotes
    Commercial Relationships L Jay Katz, Bausch & Lomb (C), Allergan (R), Allergan (C), Allergan (F), Lumenis (R), Lumenis (F); Paul Kaufman, Alcon (C), Allergan (C), Altheos, Inc (C), Bausch & Lomb (C), Amakem Therapeutics (C), Johnson & Johnson (C), Lens AR, Inc (F), Merck (C), Pfizer (C), Santen (C), WARF (F), Z Lens, LLC (F), Alcon (R), Allergan (R), Altheos, Inc (R), Bausch & Lomb (R), Amakam Therapeutics (R), Merck (R), Pfizer (R), Santen (F), Santen (R); Tuyen Ong, Bausch and Lomb (E); Baldo Scassellati-Sforzolini, Bausch & Lomb (E); Jason Vittitow, Bauach and Lomb (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 460. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L Jay Katz, Paul Kaufman, Tuyen Ong, Baldo Scassellati-Sforzolini, Jason Vittitow; Latanoprostene Bunod 0.024% Significantly Reduces and Maintains Mean Diurnal Intra-Ocular Pressure (IOP) Compared to Latanoprost 0.005% in Subjects with Open Angle Glaucoma or Ocular Hypertension. Invest. Ophthalmol. Vis. Sci. 2013;54(15):460. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To evaluate and compare latanoprostene bunod (INN, USAN) 0.024% vs. latanoprost 0.005% ophthalmic solution in reducing and maintaining mean diurnal intraocular pressure (IOP) for up to 29 days in subjects with open angle glaucoma or ocular hypertension.


Only the latanoprostene 0.024% data are reported in this analysis; the dose-ranging data have been presented elsewhere. Following randomization, subjects were assigned to either latanoprostene bunod 0.024% (n=83) or latanoprost 0.005% ophthalmic solution (n=82). Enrollment in this dose ranging study consisted of eligible subjects with IOP ≥ 26 and ≤ 32 mmHg and a diagnosis of open-angle glaucoma or ocular hypertension. Subjects dosed once daily at 8PM for 28 days. Efficacy and safety evaluations occurred on Days 7, 14, 28, and 29. Efficacy assessments included mean diurnal IOPs and the proportion of subjects maintaining a mean diurnal IOP at ≤ 18 mmHg. Safety assessments included measurement of adverse events, best-corrected visual acuity, ocular tolerability, ocular signs, and vital sign measurements. An ANCOVA model with fixed-effect terms was performed. For the change from baseline IOP, t-tests were performed for all treatment groups.


Demographic and baseline characteristics were similar across treatment groups. Subjects had a mean age of 61.0 years, were predominantly white (77.6%), and female (66.7%) with 43.0% being naïve to treatment at the time of enrollment. At Days 7, 14, and 28, statistically greater reductions in mean diurnal IOPs were observed for latanoprostene bunod 0.024% compared with latanoprost 0.005% (8.3 vs. 7.3 mmHg, p = 0.0325; 8.9 vs. 7.7 mmHg, p = 0.0145; and 9.0 vs. 7.8 mmHg, p = 0.0051, respectively). Significantly more subjects in the latanoprostene bunod 0.024% group compared with the latanoprost 0.005% group had a study eye mean diurnal IOP ≤ 18 mmHg at Days 7 (p = 0.0057), 14 (p = 0.0464), 28 (p = 0.0061), and 29 (p = 0.026). All ocular treatment-emergent adverse events were mild or moderate in severity. The percentages of subjects with conjunctival hyperemia were similar across treatment groups.


Latanoprostene bunod 0.024% produced significantly greater reductions (~1 mmHg) in mean diurnal IOP for up to 29 days compared to latanoprost 0.005%.

Keywords: 568 intraocular pressure • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 617 nitric oxide  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.